Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™ ) and Activated Prothrombin Complex Concentrates (FEIBA™ ) to Treat Hemophilia A Patients with Inhibitors in Iran

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

GOLESTANI MINA; ESHGHI PEYMAN; RASEKH HAMID REZA; CHERAGHALI ABDOL MAJID; SALAMZADEH JAMSHID; NADERI MAJID; MANAGHCHI MOHAMMADREZA; Hoorfar Hamid; TOOGEH GHOLAMREZA; IMANI ALI; KHODAYARI MOHAMMAD TAGHI; Habibpanah Behnaz; Hantooshzadeh Razieh

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Pharmaceutical Research Year:2016 | Volume:15 | Issue:2 Page(s): 669-677

Download Full-Text

View:

212

Download:

128

Cites:

Information Journal Paper

Title

Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™ ) and Activated Prothrombin Complex Concentrates (FEIBA™ ) to Treat Hemophilia A Patients with Inhibitors in Iran

Author(s)

Keywords

AryoSeven

Cost-Effectiveness

FEIBA

Hemophilia A

Inhibitor

Abstract

Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with Inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the Cost-Effectiveness of FEIBA and AryoSeven® by Decision Analytic Model according to the Iranian healthcare system. An open label, multi-center, crossover clinical trial was designed. Patients were categorized into 3 groups based on their prior tendency to one or none of the products. To determine the premium therapeutic strategy, the Incremental Cost-Effectiveness ratio (ICER) was calculated. Protocol F led to more treatment success in group F than the other groups (P= 0. 03). Also, there was a significant statistical difference between the mean of effectiveness scores in the groups using protocol F (P = 0. 01). The effectiveness of protocol F and A were 89% and 72%, respectively. ICER cost US$ 5, 146 to manage an episode of bleeding to get one more unit of effectiveness using FEIBA VS. AryoSeven. Although the results showed that AryoSeven was more cost-effective compared to FEIBA, the two strategies were undominated. In other words, both medicines can be applied in the first line of the treatment if the cost of FEIBA was reduced. The present clinical trial was registered at IRCT website, under ID No. 2013020612380N1.

Cites

No record.

References

No record.

Cite

APA: Copy

GOLESTANI, MINA, ESHGHI, PEYMAN, RASEKH, HAMID REZA, CHERAGHALI, ABDOL MAJID, SALAMZADEH, JAMSHID, NADERI, MAJID, MANAGHCHI, MOHAMMADREZA, Hoorfar, Hamid, TOOGEH, GHOLAMREZA, IMANI, ALI, KHODAYARI, MOHAMMAD TAGHI, Habibpanah, Behnaz, & Hantooshzadeh, Razieh. (2016). Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™ ) and Activated Prothrombin Complex Concentrates (FEIBA™ ) to Treat Hemophilia A Patients with Inhibitors in Iran. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), 15(2), 669-677. SID. https://sid.ir/paper/288634/en

Vancouver: Copy

GOLESTANI MINA, ESHGHI PEYMAN, RASEKH HAMID REZA, CHERAGHALI ABDOL MAJID, SALAMZADEH JAMSHID, NADERI MAJID, MANAGHCHI MOHAMMADREZA, Hoorfar Hamid, TOOGEH GHOLAMREZA, IMANI ALI, KHODAYARI MOHAMMAD TAGHI, Habibpanah Behnaz, Hantooshzadeh Razieh. Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™ ) and Activated Prothrombin Complex Concentrates (FEIBA™ ) to Treat Hemophilia A Patients with Inhibitors in Iran. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR)[Internet]. 2016;15(2):669-677. Available from: https://sid.ir/paper/288634/en

IEEE: Copy

MINA GOLESTANI, PEYMAN ESHGHI, HAMID REZA RASEKH, ABDOL MAJID CHERAGHALI, JAMSHID SALAMZADEH, MAJID NADERI, MOHAMMADREZA MANAGHCHI, Hamid Hoorfar, GHOLAMREZA TOOGEH, ALI IMANI, MOHAMMAD TAGHI KHODAYARI, Behnaz Habibpanah, and Razieh Hantooshzadeh, “Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™ ) and Activated Prothrombin Complex Concentrates (FEIBA™ ) to Treat Hemophilia A Patients with Inhibitors in Iran,” IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), vol. 15, no. 2, pp. 669–677, 2016, [Online]. Available: https://sid.ir/paper/288634/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops